Tagged with BI

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Belgium Vincent Verschraegen, country manager of Mylan Belgium and Luxembourg, speaks about his onboarding in the company and what attracted him to join the organization. Verschraegen also discusses Mylan’s evolution from a pure generics player to a full solution healthcare provider and offers insights into Belgium’s complex biosimilar landscape as well…

Romania Arina Gholmieh introduces the Romanian affiliate of Egis, a leading pharma manufacturer in the Central and Eastern Europe (CEE) region. Gholmieh highlights the difficulties that pharma companies, and especially generic producers, face in Romania: clawback tax, pricing methodology, and a low penetration rate of biosimilar medicines.   We are passing…

Belgium PDC*Line Pharma’s Eric Halioua introduces the Belgian immuno-oncology biotech, its clinical-stage assets, the impact of the firm’s collaboration with Korean LG Chem, and future internationalisation strategies.   As a multicultural company, we believe in the future growth of Belgium’s innovative biotechnology sector. It is absolutely a country which should be…

Opinion AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the ongoing coronavirus pandemic.   Like the rest of society, executive and scientific teams working in the US generic and biosimilar pharmaceutical industries have never experienced anything quite…

Mexico Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key opinion leaders. Here, we round up three of their most talked about topics.   Government  One of the most talked-about…

Belgium Miranda Heining, general manager of Fresenius Kabi for Belgium and the Netherlands, speaks about the career path that led her to join the pharma industry and lead the affiliate, her experience managing two countries simultaneously, and the potential pitfalls in navigating Belgium’s market access landscape.   The complexity of the…

Morocco CEO Abdelhakim Tahri introduces women’s health player Gynebio Pharma, how the company is disrupting the Moroccan pharmaceutical industry through its range of contraceptive and fertility products, and his vision for regional expansion.   Our major focus when creating Gynebio Pharma was creating a company and a production facility that would…

Czech Republic Rostislav Hartman, general manager of the Czech Republic for Zimmer Biomet and who also looks after numerous countries in a dynamic region in Eastern Europe, introduces Zimmer Biomet’s historical presence in the country and how the company continues to improve the quality of care for patients, in addition to improving…

Czech Republic As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the 125-year-old German firm STADA has established a strong Czech affiliate in recent times.   The beauty of STADA is that…

Artificial Intelligence Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an antibiotic that is powerful enough to combat resistant bacteria strains via a deep learning algorithm.   AI has the power to enable biopharmaceutical companies to reduce costs and improve…

Romania Cătălin Vicol introduces Biofarm, a leading Romanian pharma producer on the verge of significant international expansion. Vicol shares his insights on the potential of the Romanian consumer healthcare (CHC) market, which accounts for 95 percent of Biofarm’s activities, and discloses his ambition of becoming the number one CHC pharmaceutical producer…